AbbVie cuts away part of its partnership with Morphic on integrin research for fibrosis

Kyle Blankenship

Despite a quiet few years, Morphic Therapeutic was once a buzzy biotech looking to move integrin research into the next generation. Now, a drug giant …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AbbVie cuts away part of its partnership with Morphic on integrin research for fibrosis

Kyle Blankenship

Sign up to read this article for free.

Bicycle Therapeutics stock sinks following release of topline data, post-hoc analyses

Inside Isomorphic Labs: Demis Hassabis’ lab-free vision for biotech’s AI future

AbbVie makes another small I&I acquisition, buying Nimble for $200M

Xaira hires former Roche exec as CMO; 'Tis the season for retirements at Alnylam, Regeneron

Gilead names Dietmar Berger CMO as it eyes R&D reset

The key to faster, more impactful research? Put patients in the driver’s seat

Ab­b­Vie cuts away part of its part­ner­ship with Mor­phic on in­te­grin re­search for fi­bro­sis

Kyle Blankenship

Sign up to read this article for free.

Bi­cy­cle Ther­a­peu­tics stock sinks fol­low­ing re­lease of topline da­ta, post-hoc analy­ses

In­side Iso­mor­phic Labs: Demis Has­s­abis’ lab-free vi­sion for biotech’s AI fu­ture

Ab­b­Vie makes an­oth­er small I&I ac­qui­si­tion, buy­ing Nim­ble for $200M

Xaira hires for­mer Roche ex­ec as CMO; 'Tis the sea­son for re­tire­ments at Al­ny­lam, Re­gen­eron

Gilead names Di­et­mar Berg­er CMO as it eyes R&D re­set

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

AbbVie cuts away part of its partnership with Morphic on integrin research for fibrosis

Bicycle Therapeutics stock sinks following release of topline data, post-hoc analyses

Inside Isomorphic Labs: Demis Hassabis’ lab-free vision for biotech’s AI future

AbbVie makes another small I&I acquisition, buying Nimble for $200M

Xaira hires former Roche exec as CMO; 'Tis the season for retirements at Alnylam, Regeneron

Gilead names Dietmar Berger CMO as it eyes R&D reset

The key to faster, more impactful research? Put patients in the driver’s seat